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Abstract
Dietary Zn recommendations vary widely across Europe due to the heterogeneity of approaches used by expert panels. Under the EURo-
pean micronutrient RECommendations Aligned (EURRECA) consortium a protocol was designed to systematically review and undertake
meta-analyses of research data to create a database that includes ‘best practice’ guidelines which can be used as a resource by future
panels when setting micronutrient recommendations. As part of this process, the objective of the present study was to undertake a syste-
matic review and meta-analysis of previously published data describing the relationship between Zn intake and status in adults. Searches
were performed of literature published up to February 2010 using MEDLINE, Embase and the Cochrane Library. Data extracted included
population characteristics, dose of Zn, duration of study, dietary intake of Zn, and mean concentration of Zn in plasma or serum at the end
of the intervention period. An intake–status regression coefficient (b^) was estimated for each individual study, and pooled meta-analysis
undertaken. The overall pooled b^ for Zn supplementation on serum/plasma Zn concentrations from randomised controlled trials and
observational studies was 0·08 (95 % CI 0·05, 0·11; P,0·0001; I 2 84·5 %). An overall b^ of 0·08 means that for every doubling in Zn
intake, the difference in Zn serum or plasma concentration is 2b^ (20·08 ¼ 1·06), which is 6 %. Whether the dose–response relationship,
as provided in the present paper, could be used as either qualitative or quantitative evidence to substantiate the daily Zn intake dose
necessary to achieve normal or optimal levels of biomarkers for Zn status remains a matter of discussion.
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Dietary Zn recommendations vary widely across Europe due
to the heterogeneity of approaches used by expert panels(1).
There is a need for a harmonised approach that is transparent
and based on the best-quality data and methods available.
Traditionally, the factorial approach is used in the deter-
mination of Zn requirements. This method seeks to estimate
the Zn intake required to meet physiological requirements
for growth, metabolism and tissue repair while replacing
obligatory losses. An alternative approach is to examine the
dose–response relationship between intake and biomarkers
of status and also between intake and health outcomes. This
information could then be integrated using a mathematical
model to provide an insight into the level of Zn intake
required for optimal health based on a range of parameters
and indices of health that are known to be dependent
upon dietary Zn intake(2). To this end, the members of the
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EURopean micronutrient RECommendations Aligned (EUR-
RECA) Network of Excellence have undertaken a series of sys-
tematic reviews of Zn intake–status relationships, according to
rigorous protocols defined by consortium members and exter-
nal experts(2). We present the results of the systematic review
and meta-analysis of the dose–response relationship between
dietary Zn intake and Zn status using novel methodology
developed by members of the EURRECA consortium.
The assessment of Zn status is notoriously problematic,
as a sensitive, specific biomarker for Zn has not yet been
identified(3). A systematic review and meta-analysis of bio-
markers of Zn status was undertaken in 2009(4). For many
putative biomarkers (such as the Zn concentrations found in
the cellular components of whole blood) there were insuffi-
cient data to arrive at a definitive conclusion regarding their
efficacy as a biomarker of Zn status; however, plasma (or
serum) Zn concentration was responsive to both Zn sup-
plementation and Zn depletion and is the most widely
reported biomarker for Zn. Hair and urine Zn concentrations
were also considered to be potentially useful biomarkers in
response to Zn supplementation.
The purpose of the present review was to systematically and
quantitatively assess the dose–response relationships relevant
to deriving Zn recommendations based on intervention studies,
cohort (nested case–control) studies and cross-sectional
studies. The specific questions to be addressed were: what is
the effect of intake on indicators of exposure or body stores
(i.e. biomarkers)? What factors affect this relationship?
The data used in the present meta-analysis were extracted
from published studies (randomised controlled trials (RCT),
prospective cohort studies, nested case–control studies and
cross-sectional studies), performed in healthy adult and elderly
populations, reporting the relationship between Zn status
(plasma or serum Zn, hair or urine Zn concentration) and
intake from supplements, fortified diets or natural food diets.
Methods
Search strategy
The present research was conducted within the framework of
the EURRECA Network of Excellence that aims to identify the
micronutrient requirements for optimal health in European
populations (http://www.eurreca.org). This research was part
of a wider review process to identify studies assessing the
effect of Zn intake on different outcomes (biomarkers of Zn
status and health outcomes). The wider searches were per-
formed of literature published up to and including February
2010 using Ovid MEDLINE, Embase (Ovid) and the Cochrane
Library (CENTRAL) using search terms for (‘study designs in
humans’) AND (Zn) AND (intake OR status). Both indexing
and text terms were used and languages included were
restricted to those spoken in the EURRECA Network (English,
Dutch, French, German, Hungarian, Italian, Norwegian,
Table 1. Ovid MEDLINE search strategy
No. Search term Results
1 randomized controlled trial.pt 280 821
2 controlled clinical trial.pt 79 998
3 randomized.ab 196 604
4 placebo.ab 117 891
5 clinical trials as topic.sh 146 242
6 randomly.ab 145 491
7 trial.ab 203 467
8 randomised.ab 38 423
9 6 or 3 or 7 or 2 or 8 or 1 or 4 or 5 734 511
10 (animals not (human and animals)).sh 4 482 479
11 9 not 10 642 665
12 (cohort* or “case control*” or cross-sectional* or “cross sectional” or case-control* or prospective or “systematic review*”).mp 768 885
13 exp meta-analysis/ or exp multicenter study/ or follow-up studies/ or prospective studies/ or intervention studies/ or
epidemiologic studies/ or case-control studies/ or exp cohort studies/ or longitudinal studies/ or cross-sectional studies/
1 013 635
14 13 or 12 1 203 767
15 14 not 10 1 154 385
16 11 or 15 1 599 094
17 ((zinc or zn or zinc sulphate or zinc gluconate or zinc acetate or methionine or zinc isotope*) adj3 (intake* or diet* or
supplement* or deplet* or status or serum or plasma or leukocyte or concentration* or expos* or fortif* or urine or hair)).ti,ab
16 681
18 Nutritional Support/ or Dietary Supplements/ or nutritional requirements/ or Breast feeding/ or exp infant food/ or bottle
feeding/ or infant formula/
63 098
19 exp Nutritional Status/ or exp Deficiency Diseases/ or supplementation/ or diet supplementation/ or dietary intake/ or exp
diet restriction/ or exp mineral intake/ or Diet/ or Food, Fortified/ or nutrition assessment/ or Nutritive Value/
176 014
20 (intake* or diet* or supplement* or deplet* or status or serum or plasma or leukocyte or concentration* or expos* or fortif*
or urine or hair).ti,ab
3 166 092
21 18 or 19 or 20 3 263 114
22 zinc/ 41 027
23 22 and 21 20 745
24 23 or 17 26 943
25 24 and 16 2410
pt, Publication type; ab, abstract; sh, subject heading; mp, multiple posting; exp, explode; adj3, words have to appear within three words of each other; ti, title.
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Polish, Spanish, Greek and Serbian). The full Ovid MEDLINE
search strategy can be found in Table 1. Reference lists of
retrieved articles and published literature reviews were also
checked for relevant studies. Authors were contacted to request
missing data or clarify methods or results. The search process
is illustrated in Fig. 1.
Criteria for the consideration of studies for the present
review
Included studies were RCT, prospective cohort studies, nested
case–control studies and cross-sectional studies in healthy
human populations that supplied Zn supplementation (RCT)
or measured dietary Zn intake with either a validated FFQ, a
7154 Abstracts identified
by  database search 5 Abstracts added by hand
from review articles
2440 Duplicates removed
4719 Abstracts screened
2557 Excluded
931 Infant, child,
pregnant, lactating
populations
1231 Adult populations
1147 Excluded
Not relevant design, not healthy
populations, not relevant status
measure, not relevant intake
measure, not relevant study
population, no baseline measures
for outcome of interest, no adequate
control group, not relevant
intervention, not reported amount
of  Zn provided, no values provided
for outcome of interest, companion
paper, only abstract available
84 Intake–status–health
final library
35 Status–health relationships
(some papers reported both
status–health and intake–health
relationships)
 Intake–status
relationships:
30 RCT 7 Observational
15 Intake–health relationships
(some papers reported both
status–health and intake–health
relationships)
Excluded from the meta-analysis:
20 RCT and 4 observational:
Participants not healthy,
insufficient data reported,
duplicate data, dose unclear,
duration unclear
Included in the meta-
analysis:
10 RCT 3 Observational
Fig. 1. Study selection process for systematic review. RCT, randomised controlled trial (a colour version of this figure can be found online at http://www.journals.-
cambridge.org/bjn).
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dietary history method, a 24 h recall method for at least 3 d, or
a food record/diary for at least 3 d (observational studies).
Studies had to be conducted in apparently healthy adult and
elderly (human) populations aged $18 years and supplied Zn
supplementation either as capsules or part of a fortified meal.
If supplemental Zn was provided as a component of a fortified
meal, studies were only considered acceptable if Zn was the
only constituent that was different between treatment groups.
Biomarkers of Zn status included plasma/serum, urine and
hair Zn concentrations. Only studies that reported sufficient
data or had sufficient data obtainable from the authors to
estimate b^ and SE(b^) for the assumed linear relationship on the
loge–loge scale were included. Studies were excluded if they
were a group RCT (community trial), or were commentaries,
reviews or duplicate publications from the same study. Studies
were excluded if adults were hospitalised, had a chronic disease
or if supplemental Zn was provided for less than 2 weeks.
Selection of articles
Of 4719 identified articles in the wider search on Zn intake,
status and priority health outcomes in all populations, 2557
were excluded based upon screening of the title and abstract.
Two independent reviewers screened 10 % of the abstracts
in duplicate and any discrepancies were discussed before
screening the remaining references. Following subdivision
into appropriate population groups, the full texts of the 1231
manuscripts were assessed to determine inclusion and exclu-
sion by two independent reviewers and disagreements rectified
through discussion. A total of 1147 studies were excluded
because they did not meet the inclusion criteria. Of the remain-
ing eighty-four studies, fifty-four were excluded as they related
either Zn intake or status directly to a health endpoint, but they
had not investigated the relationship between Zn intake and
Zn related to biomarkers. A further seventeen studies were
excluded from the meta-analysis because study participants
were not healthy, insufficient data were reported, data were
duplicated, or the dosage and duration were unclear. For
the purpose of the present meta-analysis, ten RCT and three
observational studies remained. The characteristics of the
included studies are presented in Tables 2 and 3, respectively.
Data extraction
For each of the identified papers, data were extracted indepen-
dently by two reviewers into a standardised database. Extracted
data included population characteristics, dose of Zn in inter-
vention and placebo supplements, duration of the study, dietary
intake of Zn, and mean concentration of Zn in plasma or serum
at the end of the intervention period. Serum/plasma Zn con-
centrations were converted to mmol/l when applicable.
Data synthesis
Of the RCT, two that reported data for two Zn-treated groups
and two control groups were treated as two independent
estimates in the analysis(5,6). Where RCT provided outcome
data for two or more Zn-treated groups, they were included
as separate estimates in the meta-analysis(7–11). Where Zn
status was measured at different time points within the same
population only the final measure was used in the anal-
ysis(12,13). One observational study reported data from males
and females and these were treated as two estimates in the
meta-analysis(14). If dietary intake of Zn (in addition to the
intervention) was not reported in the RCT, a value of
9·7 mg/d was imputed, which was the mean dietary intake
level of the RCT that did report dietary Zn intake. As mean
baseline serum/plasma Zn concentrations were infrequently
reported in the RCT, the serum/plasma Zn concentrations in
the control group were used as a proxy of the baseline
serum/plasma Zn concentrations for our analyses.
Statistical analyses
A stratified random-effects meta-analysis was conducted using
STATA (version 11; StataCorp LP), with one subgroup combin-
ing the evidence from RCT and the other subgroup combining
the evidence from observational studies. As serum/plasma Zn
levels have been reported to decline with age(15), a separate
stratified random-effects meta-analysis compared Zn intake
and status according to age in RCT (,55 years and $55
years). In addition, stratified meta-analyses were also con-
ducted on dose of Zn (,35 mg/d and $35 mg/d) and trial
duration (in weeks). It was not possible to perform a strati-
fied meta-analysis for sex, because most studies included
both men and women and data were not available at the
individual level.
The transformations used to derive coherent single-study
estimates from the available summary statistics per study
have been described elsewhere(16). In short, an intake–
status regression coefficient (b^) for each individual study
was estimated from the mean serum/plasma Zn concen-
trations, based on the assumption of a linear relationship on
the loge–loge scale (natural logarithm of intake v. natural log-
arithm of status). Algebraically deriving an estimate from each
study of the regression coefficient (b^) and its standard error
(SE(b^)) enabled a comparison of the results from studies
with heterogeneously reported associations and effects. The
overall pooled b^ and SE(b^) were calculated using random-
effects meta-analysis, which estimates the between-study var-
iance using the method of DerSimonian & Laird(17). This was
then used to modify the weights used to calculate the sum-
mary estimate. Residual heterogeneity between studies was
evaluated using the I 2 statistic. To evaluate potential sources
of heterogeneity, the variables study duration, age, sex and
Zn dose were added simultaneously to a meta-regression
model as continuous variables. The statistical transformations
to obtain b^ and SE(b^) were performed using GenStat version
13-SP2 (VSN International Ltd) and the meta-analysis was
performed using STATA (version 11.0; StataCorp LP), with
statistical significance defined as P,0·05.
Assessment of risk of bias in included studies
In order to assess the quality of the included studies and the
risk of bias, indicators of internal validity were collected
Zinc intake and plasma zinc concentration 1965
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during data extraction (Table 3). Based on the indicators two
independent reviewers assessed the overall risk of bias and
disagreements resolved by discussion. The criteria for judging
these indicators were adapted from the Cochrane Handbook
for Systematic Reviews(18).
Results
A total of twenty estimates of Zn intake and serum/plasma Zn
status in ten RCT and four estimates in three observational
studies were eligible for meta-analysis. All studies were pub-
lished between 1979 and 2010. Although plasma/serum, urine
and hair Zn concentrations were included as markers of status
in the systematic review protocol, only plasma/serum Zn con-
centration was reported universally and sufficiently frequently
to be used in the meta-analysis. Most studies included, but did
not differentiate between, males and females, but three studies
included only females(9,19,20), two included only males(8,13) and
one provided both male and female data(14). Studies were con-
ducted in Europe (n 7), North America (n 3), South Asia (n 1),
East Asia (n 1) and Australasia (n 1) and ages of participants
ranged from 18 to 106 years.
All but one RCT used a parallel design. Boukaı¨ba et al.(6)
employed a cross-over RCT design. The RCT included 1285
participants in total with sample sizes ranging from five to
201. The median duration of the trials was 25 weeks (range
2–52 weeks). In nine studies Zn was supplemented alone at
doses ranging from 15 to 135·3 mg/d and in one study Zn
was provided within a multi-micronutrient supplement(12).
Most studies (n 7) provided the Zn supplements in the form
of zinc gluconate, but others used zinc sulfate(5), zinc acet-
ate(7) or zinc carnosine(11). Habitual Zn intakes ranged from
5·4 to 10·8 mg/d (where data were provided).
The observational studies included 1184 participants in total
with sample sizes in the range of 170–500. Zn intake was
measured using a combination of FFQ and 24 h recall, or
Table 2. Randomised controlled trials (n 10) reporting the effect of dietary zinc intake on serum/plasma zinc status in adults.
Study, year, country Sex, age Treatment groups
Micronutrient
type Duration
Status marker reported
and analytic method
Abdulla & Svensson (1979)(5),
Sweden
Mean age 25 years
SD, age range and sex
not reported
Study 1
Placebo (n 5)
135·3 mg Zn/d (n 7)
Zinc sulfate 12 weeks Plasma Zn, AAS
Study 2
Placebo (n 8)
45 mg Zn/d (n 7)
Bogden et al. (1988)(7), USA Males and females aged
60–89 years
Placebo (n 36)
15 mg Zn/d (n 36)
100 mg Zn/d (n 31)
Zinc acetate 3 months Plasma Zn, AAS
Boukaı¨ba et al. (1993)(6),
France
Males and females aged
73–106 years
BMI # 21 kg/m2
Placebo (n 21)
20 mg Zn/d (n 21)
Zinc gluconate 8 weeks Serum Zn, AAS
BMI $24 kg/m2
Placebo (n 23)
20 mg Zn/d (n 23)
Preziosi et al. (1998)(12),
France
Males and females aged
35–60 years
Placebo (n 200)
Multi-micronutrient
supplement
(20 mg Zn/d) (n 201)
Zinc gluconate 3 and
6 months
Serum Zn, AAS
Sullivan et al. (1998)(13), USA Males aged 19–35 years Placebo (n 13)
50 mg Zn/d (n 13)
Zinc gluconate 15 d Plasma Zn, AAS
Feillet-Coudray et al. (2005)(8),
France
Males aged 58–68 years Placebo (n 16)
15 mg Zn/d (n 16)
30 mg Zn/d (n 16)
Zinc gluconate 6 months Plasma Zn, ICP-MS
Feillet-Coudray et al. (2006)(9),
France
Females aged
55–70 years
Placebo (n 16)
15 mg Zn/d (n 16)
30 mg Zn/d (n 15)
Zinc gluconate 6 months Serum Zn, ICP-MS
Hininger-Favier et al. (2007)(10),
France, UK, Italy
Males and females aged
55–85 years
Age 55–70 years
Placebo (n 63)
15 mg Zn/d (n 60)
30 mg Zn/d (n 65)
Zinc gluconate 6 months Serum Zn, AAS
Age .70 years
Placebo (n 67)
15 mg Zn/d (n 66)
30 mg Zn/d (n 66)
Prasad et al. (2007)(24), USA Males and females aged
55–87 years
Placebo (n 25)
45 mg Zn/d (n 24)
Zinc gluconate 12 months Plasma Zn, AAS
Sakagami et al. (2009)(11),
Japan
Males and females aged
21–77 years
Placebo (n 28)
17 mg Zn/d (n 27)
34 mg Zn/d (n 26)
68 mg Zn/d (n 28)
Zinc carnosine 12 weeks Serum Zn, AAS
AAS, atomic absorption spectroscopy; ICP-MS, inductively coupled plasma MS.
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24 h recall alone and values ranged from 8·6 to 12·2 mg/d. The
meta-analysis of available studies suggested that Zn sup-
plementation was associated with increased serum/plasma
Zn concentrations. The estimated effect for Zn supplemen-
tation on serum/plasma Zn concentrations from RCT and
observational studies was 0·08 (95 % CI 0·05, 0·11;
P,0·0001; I 2 84·5 %) (Fig. 2). When datasets were grouped
according to study design, only the RCT showed a significant
effect size (0·09; 95 % CI 0·07, 0·120; P,0·0001; I 2 79·1 %).
Since a base-e logarithmic transformation was applied to
the Zn intake and serum/plasma Zn concentration before
calculation of the study-specific b^, the overall b^ represents
the difference in the loge-transformed predicted value of
serum/plasma Zn status for each one-unit difference in the
loge-transformed value in Zn intake. Therefore, an overall b^
of 0·08 means that for every doubling in Zn intake, the differ-
ence in Zn serum or plasma concentration is 2b^ (20·08 ¼ 1·06),
which is 6 %. This means that an individual with a Zn intake
of 14 mg/d has a Zn serum/plasma concentration that
is 6 % higher than an individual who has a Zn intake of
7 mg/d (Fig. 3).
As plasma/serum Zn concentrations have been reported to
decline with age(15), a separate subgroup analysis compared
Zn intake and status according to age in RCT (,55 years
and $55 years). Of the studies, two for which mean serum/
plasma Zn values were given for adults whose ages spanned
both age groups were excluded from this analysis(11,12).
A stronger effect size was found in adults aged under 55
years (0·14; 95 % CI 0·04, 0·24; P,0·005; I 2 92·1 %) compared
with adults aged 55 years and over (0·09; 95 % CI 0·07, 0·11;
P,0·0001; I 2 32·8 %), although care should be taken with
interpreting this finding as the younger age group analysis is
based on only three estimates in two studies. Stratifying the
analysis for dose of Zn (,35 mg/d and $35 mg/d) revealed
a stronger effect size for a Zn dose $35 mg/d (0·14; 95 % CI
0·08, 0·21; P,0·0001; I 2 85·2 %) compared with ,35 mg/d
(0·09; 95 % CI 0·07, 0·10; P,0·005; I 2 27·6 %). Similar effect
sizes were demonstrated for study duration (0–12 weeks:
0·13; 95 % CI 0·05, 0·20; I 2 92·4 %; .12 weeks: 0·10; 95 % CI
0·07, 0·12; I 2 75·8 %).
To evaluate potential sources of heterogeneity, the variables
duration, age, sex and dose were added simultaneously to a
meta-regression model as continuous variables. The analysis
revealed that only Zn dose was a statistically significant deter-
minant of the overall b. The model explained 50 % of
between-study variance and the residual variation due to het-
erogeneity was reduced to 48·2 %.
Table 4 summarises the internal validity of the included
studies, assessed as described in the Methods section. The
risk of bias was high in five out of the ten papers(5,6,11–13).
Papers were given a high risk of bias rating due to insufficient
information provided on sequence generation and/or allo-
cation, drop-outs and funding bodies.
Discussion
The present review is unique in providing an estimate of the
dose–response relationship of Zn intake and serum/plasmaT
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Zn concentrations in adults. A meta-analysis of twenty esti-
mates in ten RCT and four estimates in three observational
studies found that Zn supplementation produced a statistically
significant increase in serum/plasma Zn concentrations and
provided an estimate of the dose–response relationship
between Zn intake and serum/plasma concentrations. An
overall b^ of 0·08 means that for every doubling in Zn intake,
the difference in Zn serum or plasma concentration is 6 %.
In other words, an adult with a Zn intake of 14 mg/d has a
Zn serum/plasma concentration that is 6 % higher than an indi-
vidual who has a Zn intake of 7 mg/d. This association was
slightly stronger when considering only the RCT, as no obser-
vational studies found a significant association between Zn
intake and plasma Zn concentrations. The intake–status
regression coefficient for the observational studies is likely
to be attenuated by random and intake-related errors in asses-
sing dietary Zn intake(21), whereas in RCT Zn intake can be
considered as fixed at each level of dosage and random
errors arise only through assessment of biomarkers.
The studies included in the present meta-analysis were
different in a number of aspects, such as using various
designs, follow-up times, Zn doses and populations. There-
fore, it is no surprise that, when combining these studies in
a meta-analysis, large heterogeneity is observed between the
studies (I 2 84·5 %; P¼0·0001). This between-study heterogen-
eity may be caused by methodological factors, such as differ-
ences in study population characteristics (age, socio-economic
status) or differences in doses of provided Zn (amount, one or
more doses per d, study duration). When considering some
key variables (study duration, Zn dose, age and sex) in a
meta-regression model, only dose explained some between-
study heterogeneity. An individual participant data meta-anal-
ysis may have provided a more conclusive explanation of the
between-study heterogeneity in the present meta-analysis.
However, this type of analysis would involve the input of
raw individual participant data provided by the original
study investigators for reanalysis and combination in a
pooled analysis and as such would be a major undertaking
in terms of time, costs and collaboration. Moreover, an
inability to include individual participant data from all relevant
studies could introduce selection bias. The meta-analytic
approach used in the present paper is not an attempt to
Note: Weights are from random-effects analysis
Overall  (I 2 84·5 %, P = 0·000)
Sakagami (2009)(11) (17 mg/d)
Subtotal  (I 2 54·1 %, P = 0·088)
Prasad (2007)(24) (15 mg/d)
Boukaïba (1993)(6) (20 mg/d) BMI ≥ 24 kg/m2
Feillet-Coudray (2006)(9) (15 mg/d) females
Sakagami (2009)(11) (68 mg/d)
Abdulla (1979)(5) (45 mg/d)
Sánchez (2009)(14)
Hininger-Favier (2007)(10) (30 mg/d) age 55–70 years
Gibson (2001)(19)
Sánchez (2009)(14)
Feillet-Coudray (2005)(8) (30 mg/d) males
Sakagami (2009)(11) (34 mg/d)
Subtotal  (I 2 79·1 %, P = 0·000)
Sullivan (1998)(13) (50 mg/d)
Hininger-Favier (2007)(10) (15 mg/d) age 55–70 years
Bogden (1988)(7) (100 mg/d)
Hininger-Favier (2007)(10) (30 mg/d) age >70 years
Abdulla (1979)(5) (135·3 mg/d)
Boukaïba (1993)(6) (20 mg/d) BMI ≤ 21 kg/m2
Preziosi (1998)(12) (20 mg/d)
Feillet-Coudray (2005)(8) (15 mg/d) males
Observational studies
Chandyo (2009)(20)
Hininger-Favier (2007)(10) (15 mg/d) age >70 years
Feillet-Coudray (2006)(9) (30 mg/d) females
Bogden (1988)(7) (15 mg/d)
Randomised controlled trials
Study
0·08 (0·05, 0·11)
0·02 (–0·08, 0·12)
0·02 (–0·05, 0·10)
0·17 (0·08, 0·25)
0·11 (–0·01, 0·22)
0·11 (–0·01, 0·23)
0·09 (0·03, 0·15)
0·15 (0·07, 0·23)
0·09 (–0·03, 0·22)
0·03 (–0·04, 0·09)
–0·03 (-0·07, 0·00)
0·10 (–0·04, 0·23)
0·11 (0·04, 0·19)
0·09 (0·03, 0·15)
0·09 (0·07, 0·12)
0·06 (0·01, 0·11)
0·07 (0·03, 0·11)
0·11 (0·08, 0·14)
0·06 (0·00, 0·13)
0·20 (0·18, 0·22)
0·13 (0·08, 0·17)
0·09 (0·06, 0·12)
0·05 (–0·04, 0·14)
–0·00 (–0·15, 0·14)
0·06 (0·01, 0·11)
0·10 (0·03, 0·17)
0·04 (–0·02, 0·11)
β (95 % CI)
0–0·5 0·5
Fig. 2. Random-effects meta-analyses of randomised controlled trials and observational studies evaluating the pooled effect of dietary zinc on serum/plasma zinc
in adults. b Values (V) represent the regression coefficients for the linear association between loge-transformed zinc intake and loge-transformed serum/plasma
zinc status (a colour version of this figure can be found online at http://www.journals.cambridge.org/bjn).
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accurately describe the biological relationship between actual
Zn intake and Zn concentrations in blood under strict exper-
imental conditions and on an individual level, but rather to
simulate a dose–response relationship between Zn intake
and status that is useful for surveillance studies with a public
health point of view and, as such, deliberately incorporates
the differences between dietary assessment methods, labora-
tory assessment methods and participant characteristics to
ensure a broad external validity. Thus, the heterogeneity
reflects the lack of standardisation of methods and the true
heterogeneity between study populations and necessarily
enters as uncertainty into the application of such data for
public health purposes(22).
To conduct the present meta-analysis some assumptions
related to the availability of the required data or related to
statistical issues had to be made. First, when two or more
intervention groups were compared with the same control
group (five RCT), independence of estimates was assumed.
As a consequence, bias may have been introduced, by either
increasing the estimates of the intervention effect (if the con-
trol group values were in fact lower), or decreasing the
estimates of the intervention effect (if the control group
values were higher). Second, the meta-analysis required
transformations of the intake and biomarker data to a common
scale, as the studies included in the present meta-analyses had
different ways of reporting the relationship between Zn and
serum/plasma Zn concentration. Thedifferentways of reporting
by transformation of both the intake and biomarker data
were standardised to double loge scale, which allowed the
derivation of a standardised estimate from each study of the
regression coefficient and its standard error as a basis for
comparing these heterogeneously reported results. A linear
relationship on the double loge scale was also assumed.
This transformation allowed the pooling of b values and
enable these to be reported as a dose–response relationship
between Zn intake and serum/plasma Zn concentrations(16).
The meta-analyses were conducted within the context of
the EURRECA project as a means to provide additional evi-
dence for underpinning reference values for Zn intake of
populations. This dose–response relationship methodology
may be used as either qualitative or quantitative evidence to
substantiate the daily Zn intake dose necessary to achieve
normal or optimal levels of biomarkers for Zn status. The
dose–response relationship between Zn intake and plasma Zn
concentration is of course subject to the debate around the
usefulness of plasma/serum Zn concentration as a biomarker
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Fig. 3. Serum/plasma zinc concentration (mmol/l) as a function of dietary zinc intake (mg/d), estimated by random-effects meta-analyses of randomised controlled
trials of adults: natural log-transformed data (a); untransformed data (b).
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of Zn status, and its predictive value for relevant functional
health outcomes, such as markers of immune function.
The relationship observed between serum/plasma Zn
concentration and Zn intake may have been weakened by the
limitation of this particular biomarker for Zn status. It is well
established that plasma Zn concentration can fall in response
to factors unrelated to Zn status or dietary Zn intake, such as
infection, inflammation, exercise, stress or trauma(23). Conver-
sely, tissue catabolism during starvation can release Zn into
the circulation, causing a transient increase in circulating Zn
levels. A total of six studies used non-fasted blood samples in
their analyses(5,7,11,14,20,24). As postprandial plasma Zn concen-
trations have been reported to fall up to 19 %(25), the inclusion of
these studies may have weakened the observed relationship
between Zn intake and status. Whilst all studies included in
the analysis were undertaken in individuals without chronic dis-
ease or severe protein–energy malnutrition, other factors such
as stress, infection and inflammation may also have gone unre-
ported. In addition, serum Zn concentration has been reported
to decrease with age(15). Clearly, such confounders have a
strong influence on the interpretation of plasma Zn concen-
trations. However, as more sensitive indices of Zn status have
yet to be identified, plasma serum Zn remains by far the most
commonly used biomarker of Zn status(4).
In conclusion, the present review presents the application
of a novel technique to analyse data from ten RCT and three
observational studies reporting the relationship between Zn
intake and serum/plasma Zn concentration. The present
meta-analysis has provided an estimate of the dose–response
relationship between Zn intake and serum/plasma Zn concen-
tration in adult and elderly populations. Based on twenty-four
estimates among 2469 participants, the results indicate that a
doubling of Zn intake increases plasma/serum levels by 6 %.
There is a high level of heterogeneity in the data obtained
from the studies included in this meta-analysis. Analysis of
the factors that may contribute to this, namely study duration,
Zn dose, age and sex, indicated that Zn dose was able to
explain 50 % of this heterogeneity. This novel method of ana-
lysing intake–biomarker relationships may be useful for the
setting of future dietary Zn recommendations.
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